葡萄糖类-1受体激活剂对2型糖尿病患者吸烟消费的影响:随机并行控制临床试验的研究方案
相关实验视频
Updated: Feb 19, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
95.9K
Da Chen1, Ziyi Li1, Chenxia Zhou1
1Department of Endocrinology, East Hospital, Tongji University School of Medicine, Shanghai, China.
Frontiers in clinical diabetes and healthcare
|February 18, 2026
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs) 可能减少2型糖尿病患者的尼古丁依赖. 这项试验调查了GLP-1RA对吸烟和大脑活动的影响,正在进行招募.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 成 药物 药物 药物 药物
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的2型糖尿病 (T2DM) 治疗方法.
- GLP-1RAs可能调节奖励通路,这表明它可能在管理尼古丁依赖方面发挥作用.
- 有限的随机对照试验证据表明GLP-1RA对T2DM患者吸烟的影响.
研究的目的:
- 评估GLP-1RAs在T2DM患者中减少尼古丁依赖的疗效.
- 评估GLP-1RAs对吸烟暴露和戒烟率的影响.
- 使用功能磁共振成像 (fMRI) 探索潜在的GLP-1RA对吸烟行为的潜在神经机制.
主要方法:
- 一个单中心,并行组随机对照试验,招募了46名T2DM和尼古丁依赖的男性成年人 (Fagerström尼古丁依赖测试 (FTND) 分数≥4).
- 参与者被随机分配到24周内接受GLP-1RA或二乙酶-4抑制剂 (DPP-4i).
- 主要结果是FTND得分的变化,次要结果包括呼出的一氧化碳水平和戒烟率. 探索性fMRI措施也被评估.
主要成果:
- 该部分尚未提供,因为试验正在进行中.
结论:
- 该部分尚未提供,因为试验正在进行中.
相关概念视频
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Dipeptidyl Peptidase 4 Inhibitors
734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
Oral Hypoglycemic Agents: Glinides
707
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
707
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
Drugs Acting on Autonomic Ganglia: Stimulants
2.1K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.1K

